ALVR: AlloVir, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 83.71
Enterprise Value ($M) -6.41
Book Value ($M) 145.78
Book Value / Share 1.31
Price / Book 0.57
NCAV ($M) 142.62
NCAV / Share 1.28
Price / NCAV 0.59

Profitability (mra)
Return on Invested Capital (ROIC) -1.10
Return on Assets (ROA) -0.69
Return on Equity (ROE) -0.85

Liquidity (mrq)
Quick Ratio 6.61
Current Ratio 6.61

Balance Sheet (mrq) ($M)
Current Assets 187.63
Assets 190.80
Liabilities 45.02
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -181.33
Net Income -190.42
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -124.45
Cash from Investing 37.98
Cash from Financing 70.50

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-13 13G/A Gilead Sciences Inc 14.60 21.39
02-09 13G/A Fmr Llc 4.99 -19.21
02-09 13G/A Artal International S.C.A. 5.80 18.29
02-01 13G EcoR1 Capital, LLC 9.30
01-09 13G Wilson John Robert 8.98

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-08-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-05-04 10-Q Form 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-03-27 68,954 1,362,996 5.06
2024-03-26 102,231 339,146 30.14
2024-03-25 314,385 560,209 56.12
2024-03-22 29,315 286,155 10.24

(click for more detail)

Similar Companies
ALLK – Allakos Inc. ALLO – Allogene Therapeutics, Inc.
ALNY – Alnylam Pharmaceuticals, Inc. ALXO – ALX Oncology Holdings Inc.
AMGN – Amgen Inc.


Financial data and stock pages provided by
Fintel.io